Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 196 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: buprenorphine (Suboxone) Clear all
Suspended No phase listed Observational Accepts healthy volunteers

Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

NCT05121428
View directory record Official record
Conditions
Opioid-use Disorder, Acceptability of Health Care, Opioid-Related Disorders
Interventions
Not listed
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 5, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

Prescription Opioid Addiction Treatment Study (POATS)

NCT00316277
View directory record Official record
Conditions
Opiate Dependence, Substance-related Disorders, Opioid-related Disorders
Interventions
Standard Medical Management (SMM) of Prescription Opiate Abuse, Enhanced Medical Management (EMM) of Prescription Opiate Abuse
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Lawrenceburg, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 5, 2026, 1:34 PM EDT
Withdrawn No phase listed Observational

Measures to Improve Outcomes After an Opioid Overdose

NCT03968237
View directory record Official record
Conditions
Opioid Overdose
Interventions
Buprenorphine/Naloxone
Drug
Lead sponsor
Nassima Ait-Daoud Tiouririne
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 5, 2026, 1:34 PM EDT
Completed Phase 3 Interventional

Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1

NCT00078130
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
14 Years to 21 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
4
States / cities
Portland, Maine • Baltimore, Maryland • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 5, 2026, 1:34 PM EDT
Completed Phase 4 Interventional Results available

Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients

NCT01559454
View directory record Official record
Conditions
Low Back Pain
Interventions
Methadone, Buprenorphine/naloxone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 5, 2026, 1:34 PM EDT
Completed Phase 2 Interventional

Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants

NCT00130819
View directory record Official record
Conditions
Opiate Dependence, HIV Seropositivity, HIV Infections
Interventions
Clinic-based substance abuse treatment with buprenorphine, Case management and referred substance abuse treatment
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 5, 2026, 1:34 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075

NCT03248947
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
buprenorphine/naloxone, Pharmacist-administered buprenorphine/naloxone maintenance care
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 5, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Maternal Buprenorphine-naloxone Treatment and the Infant

NCT03291847
View directory record Official record
Conditions
Maternal Opioid Use Disorder, Opioid Exposed Infant
Interventions
fetal monitoring, Buprenorphine Naloxone
Device · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 5, 2026, 1:34 PM EDT
Completed No phase listed Observational

MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study

NCT03718104
View directory record Official record
Conditions
Opioid-use Disorder, Neonatal Abstinence Syndrome, Pregnancy, High Risk, Alcohol Use Disorder
Interventions
Pharmacokinetic analysis, Safety and Efficacy, Genetic and epigenetic analysis, Breast milk analysis
Other · Genetic
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Carrboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 5, 2026, 1:34 PM EDT
Withdrawn Not applicable Interventional

Opiate Craving Reduction Study Using Post-detox Patients on Suboxone and Use of TEAS as Adjunctive Treatment

NCT02033746
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Han's Acupoint Nerve Stimulator
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 5, 2026, 1:34 PM EDT
Completed Phase 3 Interventional

Linking Hospitalized Injection Drug Users to Buprenorphine

NCT00987961
View directory record Official record
Conditions
Opiate Dependence
Interventions
Linkage
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 5, 2026, 1:34 PM EDT
Completed No phase listed Observational

Using mHealth to Aid Opioid Addicts

NCT01955902
View directory record Official record
Conditions
Opiate Dependency Relapse
Interventions
Not listed
Lead sponsor
Care Team Solutions
Industry
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 5, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Assessing the Safety of Buprenorphine in People With Sickle Cell Disease

NCT03492099
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
buprenorphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 5, 2026, 1:34 PM EDT
Completed Phase 1 Interventional

Buprenorphine and Naloxone Combination Study - 10

NCT00015288
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 5, 2026, 1:34 PM EDT
Completed Not applicable Interventional Results available

SMART Effectiveness Trial

NCT04464421
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Dependence, Treatment Adherence
Interventions
Contingency Management (CM), Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)
Behavioral
Lead sponsor
Karen Derefinko, PhD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 5, 2026, 1:34 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation

NCT03420313
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine/naloxone sublingual tablets
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 5, 2026, 1:34 PM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

NCT03616236
View directory record Official record
Conditions
Opioid Use
Interventions
Buprenorphine/Naloxone, Treatment as usual
Drug · Other
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 5, 2026, 1:34 PM EDT
Terminated Phase 3 Interventional Results available

Virginia Opioid Overdose Treatment InitiatVE

NCT03818399
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
SUBLOCADE
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 5, 2026, 1:34 PM EDT
Completed Not applicable Interventional

Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy

NCT02243670
View directory record Official record
Conditions
Opiate Addiction, Medication Non-adherence, Addiction, Opioid Dependence
Interventions
AiCure monitoring and intervention
Device
Lead sponsor
AiCure
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 5, 2026, 1:34 PM EDT
Completed Not applicable Interventional

SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence

NCT04080180
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Contingency Management, Brief Motivational Interviewing + Substance Free Activities + Mindfulness
Behavioral
Lead sponsor
Karen Derefinko, PhD
Other
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 5, 2026, 1:34 PM EDT
Completed Phase 3 Interventional

Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)

NCT06023459
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
Interventions
Injectable extended-release buprenorphine, Sublingual buprenorphine-naloxone
Drug
Lead sponsor
Yih-Ing Hser
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
El Dorado, Arkansas • Garberville, California • Gibson City, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 5, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Suvorexant for Opioid/Stimulant Co-use

NCT05546515
View directory record Official record
Conditions
Opioid Use Disorder, Stimulant Use Disorder
Interventions
Suvorexant (dual orexin receptor antagonist), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 5, 2026, 1:34 PM EDT
Terminated No phase listed Observational

The Effects of Opioid Taper on Opioid-Induced Hyperalgesia

NCT03063905
View directory record Official record
Conditions
Buprenorphine, Pain
Interventions
Buprenorphine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Timeline
2017 – 2018
U.S. locations
2
States / cities
Rockville, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 5, 2026, 1:34 PM EDT
Not yet recruiting Phase 4 Interventional

Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation

NCT07469501
View directory record Official record
Conditions
Opioid Use Disorder, Fentanyl
Interventions
Injectable buprenorphine, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 5, 2026, 1:34 PM EDT